Piper Sandler reiterates Climb Bio stock rating after ASN data
Piper Sandler reiterated an Overweight rating and $40 price target for Climb Bio (CLYM) after data presentations at the American Society of Nephrology meeting. The firm highlighted positive Phase 1 data for CLYM116 and budoprutug, with key Phase 2 and 3 milestones expected in 2027. CLYM stock has fallen 18% in a week to $9.21, despite a 319% gain over the past year. Analysts maintain strong buy consensus with price targets ranging from $18 to $35.
How this was made
The 30-second read
Why it matters
Analyst consensus upgrades and higher price targets reflect belief that the early data de‑risk the programs, potentially driving the stock higher in the short term.
Market read
The article provides fresh analyst upgrades and clinical data, offering a short‑term catalyst for CLYM.
What to watch
Phase 2 and Phase 3 data are still months away, and the market may price in risk of trial failure.
Background
Climb Bio (NASDAQ:CLYM) is a small‑cap biotech focused on autoimmune kidney diseases. Recent presentations at the American Society of Nephrology highlighted early trial results for its lead candidates.
Ticker impact
Piper Sandler reiterated Overweight and a $40 price target for Climb Bio after fresh ASN clinical data on CLYM116 and budoprutug.
likely upside as investors price in the new data and higher target.
Multiple analysts raised targets and upgraded the stock on the same day new data were presented, indicating fresh catalyst.
Market effects
Positive data may lift other biotech firms developing autoimmune therapies.
US biotech sector could see modest gains.
Limited to investors focused on clinical‑trial driven biotech stocks.
Counterpoint
The stock has fallen 18% this week; some may view the upgrades as premature without longer‑term data.
Key entities
- analystPiper Sandler
Reiterated Overweight rating and $40 target.
- analystGuggenheim
Maintained Buy rating with $35 target.
- analystDeutsche Bank
Initiated coverage with $28 target.
